News & Publications

Glasmacinal, a macrolide with negligible antimicrobial activity but with anti-inflammatory and immunomodulatory properties, was well tolerated in healthy participants and has limited potential for clinically relevant drug interactions.

EpiEndo Pharmaceuticals announces the publication of preclinical research in the international peer-reviewed journal, Biomedicines.

EpiEndo has raised €5m of new funding from new and existing investors via a €9m convertible bond issuance.

Glasmacinal, a novel macrolide, was shown to be well tolerated and reduced neutrophilic inflammation in COPD patients.

The presentation, ‘EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients’, will highlight preclinical data produced through EpiEndo’s collaboration with Lund University.

EpiEndo Pharmaceuticals has had an article published in peer-reviewed journal, Frontiers in Allergy, highlighting the importance of the airway epithelium in lung function, both as a physical barrier and as a regulator of immune defence.

EpiEndo Pharmaceuticals has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics.

EpiEndo Pharmaceuticals is proud to participate the upcoming State Visit to Sweden, hosted by Business Iceland from 6-8 May 2025.